IDEXX Laboratories, Inc. $IDXX Shares Sold by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 59.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,381 shares of the company’s stock after selling 1,995 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IDEXX Laboratories were worth $882,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IDXX. BI Asset Management Fondsmaeglerselskab A S raised its holdings in IDEXX Laboratories by 65.7% during the third quarter. BI Asset Management Fondsmaeglerselskab A S now owns 45,029 shares of the company’s stock worth $28,769,000 after purchasing an additional 17,848 shares during the last quarter. Howe & Rusling Inc. increased its position in shares of IDEXX Laboratories by 16.9% in the third quarter. Howe & Rusling Inc. now owns 9,458 shares of the company’s stock valued at $6,043,000 after buying an additional 1,364 shares in the last quarter. Optimize Financial Inc raised its stake in shares of IDEXX Laboratories by 70.8% during the 3rd quarter. Optimize Financial Inc now owns 661 shares of the company’s stock worth $422,000 after buying an additional 274 shares during the last quarter. Savant Capital LLC boosted its position in shares of IDEXX Laboratories by 10.4% in the 3rd quarter. Savant Capital LLC now owns 4,366 shares of the company’s stock worth $2,789,000 after buying an additional 411 shares in the last quarter. Finally, J.W. Cole Advisors Inc. grew its stake in IDEXX Laboratories by 4.0% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 4,611 shares of the company’s stock valued at $2,946,000 after acquiring an additional 177 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDXX has been the subject of several recent research reports. Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday. UBS Group cut their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday. Morgan Stanley upped their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Jefferies Financial Group reissued a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $777.78.

IDEXX Laboratories Price Performance

IDXX opened at $644.61 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company’s 50 day simple moving average is $693.74 and its 200 day simple moving average is $664.06. The stock has a market capitalization of $51.47 billion, a PE ratio of 49.32, a P/E/G ratio of 3.92 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.87 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.